Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models

被引：1
|
作者：
Golfier, Sven [1 ]
Kahnert, Antje [2 ]
Heisler, King [2 ]
Kopitz, Charlotte [1 ]
Berhoerster, Kerstin [2 ]
Stelte-Ludwig, Beatrix [2 ]
Mayer-Bartschmid, Anke [2 ]
Bruder, Sandra [2 ]
Linden, Lars [2 ]
Harrenga, Axel [2 ]
Schatz, Christoph [1 ]
Kreft, Bertolt [1 ]
Mueller-Tiemann, Beate [2 ]
Ziegelbauer, Karl [1 ]
机构：
[1] Bayer HealthCare, Berlin, Germany
[2] Bayer HealthCare, Wuppertal, Germany
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-1754
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1754
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and candidate biomarker evaluation for the anti-mesothelin antibody drug conjugate (ADC) BAY 94-9343, mesothelin-ADC in mesothelin-positive preclinical xenograft models
    Schatz, Christoph A.
    Golfier, Sven
    Scheider, Claudia
    Kopitz, Charlotte
    Berhoerster, Kerstin
    Henderson, David
    Schmitz, Arndt
    Krahn, Thomas
    Kreft, Bertolt
    Ziegelbauer, Karl
    [J]. CANCER RESEARCH, 2012, 72
  • [2] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
    Bendell, Johanna
    Blumenschein, George
    Zinner, Ralph
    Hong, David
    Jones, Suzanne
    Infante, Jeffrey
    Burris, Howard
    Rajagopalan, Prabhu
    Kornacker, Martin
    Henderson, David
    Kelly, Andrea
    Hassan, Raffit
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [3] A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers
    Scales, Suzie J.
    Gupta, Nidhi
    Pacheco, Glenn
    Firestein, Ron
    French, Dorothy M.
    Chuh, Josefa
    Zhang, Yin
    Berry, Leanne
    Bostrom, Jenny
    Luis, Elizabeth
    O'Donohue, Aimee Fourie
    Kozak, Katherine R.
    Ross, Sarajane
    Dennis, Mark S.
    Tibbitts, Jay
    Spencer, Susan D.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [4] Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries
    Hsu, Hung-Ju
    Tung, Chao-Ping
    Yu, Chung-Ming
    Chen, Chi-Yung
    Chen, Hong-Sen
    Huang, Yu-Chuan
    Tsai, Pei-Hsun
    Lin, Su-, I
    Peng, Hung-Pin
    Chiu, Yi-Kai
    Tsou, Yueh-Liang
    Kuo, Wei-Ying
    Jian, Jhih-Wei
    Hung, Fei-Hung
    Hsieh, Chiao-Yun
    Hsiao, Michael
    Chuang, Simon Shih-Hsien
    Shen, Chia-Ning
    Wang, Yong Alison
    Yang, An-Suei
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells
    Lazzerini, Lea
    Joehrens, Korinna
    Sehouli, Jalid
    Cichon, Gunter
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 302 (05) : 1255 - 1262
  • [6] Nonclinical characterization and tolerability of a surrogate anti-mesothelin-MMAE antibody-drug conjugate
    Gupta, Nidhi
    Solis, Willy A.
    Fuji, Reina N.
    Oldendorp, Amy
    Pacheco, Glenn
    Luis, Elizabeth
    Chuh, Josefa
    French, Dorothy M.
    Drake, Elizabeth
    Dennis, Mark S.
    Kozak, Katherine R.
    Ross, Sarajane
    Tibbitts, Jay
    Spencer, Susan D.
    Scales, Suzie J.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [7] Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
    Hung-Ju Hsu
    Chao-Ping Tung
    Chung-Ming Yu
    Chi-Yung Chen
    Hong-Sen Chen
    Yu-Chuan Huang
    Pei-Hsun Tsai
    Su-I Lin
    Hung-Pin Peng
    Yi-Kai Chiu
    Yueh-Liang Tsou
    Wei-Ying Kuo
    Jhih-Wei Jian
    Fei-Hung Hung
    Chiao-Yun Hsieh
    Michael Hsiao
    Simon Shih-Hsien Chuang
    Chia-Ning Shen
    Yong Alison Wang
    An-Suei Yang
    [J]. Scientific Reports, 11
  • [8] Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
    Lea Lazzerini
    Korinna Jöhrens
    Jalid Sehouli
    Günter Cichon
    [J]. Archives of Gynecology and Obstetrics, 2020, 302 : 1255 - 1262
  • [9] Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers
    Wong, Po Yee
    He, Lin
    Chow, Kronos
    Wong, Kwan Wa
    O, Chui Yee
    Wong, Dennis
    Luk, John Moon
    Lo, Pui-Chi
    Wong, Kwong Fai
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [10] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
    Xu, Yan
    Liang, Junqing
    Jiang, Shuwen
    Yang, Haibin
    Zhang, Hui
    Mao, Fangfang
    Zhu, Jiahuan
    He, Jianlin
    Yang, Na
    Wang, Jian
    Zhang, WeiHan
    Ren, Yongxin
    Su, Weiguo
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345